Team
Discovering next-generation treatments for the mind and body
Joseph Tucker, Ph.D.
Chief Executive Officer, Director
Avani Kanubaddi
President & COO
Bob Dagher, M.D.
Chief Medical Officer
Peter Facchini, Ph.D.
Chief Innovation Officer
Carter Ward
Chief Financial Officer
David Johnson
Executive Chairman
George Kegler
Director and Chair of the Audit Committee
Douglas Lind, M.D.
Director
Sol Mayer
Director
Marcus Schabacker, M.D., Ph.D.
Director
Joseph Tucker, Ph.D.
Chief Executive Officer, Director
Michael J. Zelefsky, M.D.
Chairman
Vice Chair, Department of Radiation Oncology, Chief, Brachytherapy Service, Memorial Sloan Kettering Cancer Center
Specialization in Clinical Research
Professor, St. George’s University of London
Specialization in Oncology Research
Neuro-Oncologist, Sunnybrook Research Institute
Professor, University of Toronto
Specialization in Clinical Research
Professor, Neurobiology, Weizmann Institute
Specialization in Oncology Research, Patent Contributor
Brain health expert and board certified in Preventive Medicine
Coordinated $2B+ in Medical Research at the US Army Medical Research & Material Command
We Strive to Improve Outcomes with Our Novel Adjunctive CKD Therapies
Chronic kidney disease (CKD) is characterized by a gradual loss of kidney function. As many as one in nine U.S. adults has CKD. Kibow Therapeutics is advancing novel, non-invasive therapies to improve quality of life and slow the progression of CKD.